Treatment of idiopathic retroperitoneal fibrosis with combined administration of corticosteroids and tamoxifen

Τζιόμαλος, Κωνσταντίνος; Krikis, Napoleon; Karagiannis, A.; Perifanis, Vassilios; Rizopoulou, D.; Georgopoulou, Vasiliki; Harsoulis, Faidon

doi:10.5414/cnp62074

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is an increasing number of reports using tamoxifen, principally as initial medical therapy in retroperitoneal fibrosis with good results [92][93][94][95][96]. Although the mechanism of action of tamoxifen in retroperitoneal fibrosis remains unclear, additional controlled clinical trials are needed to prove its efficacy in retroperitoneal fibrosis and to apply its use in other fibrotic diseases.…”

Section: Tamoxifenmentioning

confidence: 97%

Antifibrosis: To Reverse the Irreversible

Paz

Shoenfeld

2009

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Fibrosis is a pathological process that includes scar formation and overproduction of extracellular matrix by the connective tissue as a response to tissue damage. The fibrotic process involves multiple organs and results in progressive life-threatening diseases. Today, we know more about the molecular mechanism that leads to fibrosis involving different type of cells, cytokines, chemokines, and tissue enzymes. Fibrosis was considered an irreversible process, at least clinically, and is still usually treated by anti-inflammatory and immunosuppressive agents. No proven antifibrotic therapy has shown efficacy in ameliorating the clinical course of fibrotic diseases, but our current understanding led to the development of different drugs with promising results, like: mycophenolate mofetil, interferon, relaxin, and intravenous immunoglobulin. This review will provide a glance to this heavily investigated subject.

show abstract